• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

随机尿钠/钾比值对肝硬化腹水患者利尿剂治疗反应的诊断价值。

Diagnostic usefulness of the random urine Na/K ratio in predicting therapeutic response for diuretics in cirrhotic patients with ascites.

作者信息

Mohii El Sayed M, El Mansy Ismail M, Salah Mohamed, Khedr Mohamed Abd Elhamid

出版信息

J Egypt Soc Parasitol. 2013 Dec;43(3):767-76. doi: 10.12816/0006433.

DOI:10.12816/0006433
PMID:24640876
Abstract

Ascites is a major complication of liver cirrhosis which carries a poor prognosis. Diuretics are used in treatment of ascites in addition to salt restriction. Monitoring of diuretic response can be achieved by measurement of 24 hours urinary sodium. This study evaluated the accuracy of using spot urinary sodium/potassium ratio as a reliable alternative to 24 hours urinary sodium in assessment of dietary sodium compliance in patients with liver cirrhosis receiving diuretics. Fifty patients presented with liver cirrhosis and ascites were divided into 2 groups: GI 14 (28%) patients diuretic resistant with 24 hours urinary sodium < 78 mEq) and GII 36 (72%) patients diuretic sensitive with 24 hours urinary sodium > 78 mEq. The results showed highly significant correlation between 24 hours urinary sodium and spot urine sodium/potassium ratio with sensitivity 87.5% specificity 56% and accuracy 70% at cutoff point of 1.8.

摘要

腹水是肝硬化的主要并发症,预后较差。除限制盐摄入外,利尿剂还用于治疗腹水。通过测量24小时尿钠可监测利尿剂反应。本研究评估了用随机尿钠/钾比值作为24小时尿钠的可靠替代指标,以评估接受利尿剂治疗的肝硬化患者饮食中钠依从性的准确性。50例肝硬化腹水患者分为两组:第一组14例(28%)为利尿剂抵抗患者,24小时尿钠<78 mEq;第二组36例(72%)为利尿剂敏感患者,24小时尿钠>78 mEq。结果显示,24小时尿钠与随机尿钠/钾比值之间存在高度显著相关性,在临界值为1.8时,敏感性为87.5%,特异性为56%,准确性为70%。

相似文献

1
Diagnostic usefulness of the random urine Na/K ratio in predicting therapeutic response for diuretics in cirrhotic patients with ascites.随机尿钠/钾比值对肝硬化腹水患者利尿剂治疗反应的诊断价值。
J Egypt Soc Parasitol. 2013 Dec;43(3):767-76. doi: 10.12816/0006433.
2
Spot urinary sodium for assessing dietary sodium restriction in cirrhotic ascites.用即时尿钠评估肝硬化腹水患者的饮食钠限制情况。
World J Gastroenterol. 2009 Aug 7;15(29):3631-5. doi: 10.3748/wjg.15.3631.
3
Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.通过简单易得的随机尿钠/钾比值预测托伐普坦的利尿反应。
PLoS One. 2017 Mar 31;12(3):e0174649. doi: 10.1371/journal.pone.0174649. eCollection 2017.
4
[The significance of urine sodium measurement after furosemide administration in diuretics-unresponsive patients with liver cirrhosis].[速尿给药后尿钠测定在肝硬化利尿剂无反应患者中的意义]
Taehan Kan Hakhoe Chi. 2003 Dec;9(4):324-31.
5
Diagnostic usefulness of the spot urine sodium/potassium ratio in cirrhotic patients with ascites.肝硬化腹水患者尿钠/钾比值在诊断中的作用。
PLoS One. 2021 Jun 24;16(6):e0253886. doi: 10.1371/journal.pone.0253886. eCollection 2021.
6
Can 24-h urine sodium excretion be replaced by spot urine sodium/potassium in patients with decompensated cirrhosis?
Liver Int. 2012 Jan;32(1):172-3. doi: 10.1111/j.1478-3231.2011.02669.x. Epub 2011 Oct 20.
7
Change in antikaliuretic response to potassium-sparing diuretics in patients with cirrhotic ascites.肝硬化腹水患者对保钾利尿剂的抗利尿反应变化。
J Am Geriatr Soc. 1976 Aug;24(8):340-3. doi: 10.1111/j.1532-5415.1976.tb03309.x.
8
[Diagnostic usefulness of the random urine Na/K ratio in cirrhotic patients with ascites: a pilot study].[随机尿钠/钾比值在肝硬化腹水患者中的诊断价值:一项初步研究]
Korean J Hepatol. 2010 Mar;16(1):66-74. doi: 10.3350/kjhep.2010.16.1.66.
9
The effect of diuretic treatment on red cell and plasma sodium concentration in patients with hepatic cirrhosis and ascites.
Biomedicine. 1975 Feb 28;23(2):68-72.
10
Stepped care medical treatment for cirrhotic ascites: analysis of factors influencing the response to treatment.肝硬化腹水的阶梯式医疗治疗:影响治疗反应的因素分析
J Gastroenterol Hepatol. 1995 Jan-Feb;10(1):30-5. doi: 10.1111/j.1440-1746.1995.tb01043.x.

引用本文的文献

1
Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan.托伐普坦附加给药治疗肝硬化腹水
Int J Mol Sci. 2021 May 25;22(11):5582. doi: 10.3390/ijms22115582.
2
Guidelines on the management of ascites in cirrhosis.肝硬化腹水管理指南。
Gut. 2021 Jan;70(1):9-29. doi: 10.1136/gutjnl-2020-321790. Epub 2020 Oct 16.
3
HEP-Net opinion on the management of ascites and its complications in the setting of decompensated cirrhosis in the resource constrained environment of Pakistan.HEP-Net关于在巴基斯坦资源有限环境下失代偿期肝硬化患者腹水及其并发症管理的意见。
Pak J Med Sci. 2020 Jul-Aug;36(5):1117-1132. doi: 10.12669/pjms.36.5.2407.